Publication Name	World Journal of Diabetes
Manuscript ID	89337
Country	United Kingdom

Received	2023-10-28 21:04
Peer-Review Started	2023-10-28 21:04
To Make the First Decision
Return for Revision	2023-12-29 06:47
Revised	2024-01-02 06:54
Second Decision	2024-02-05 10:42
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2024-02-18 08:22
Articles in Press	2024-02-18 08:22
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-02-29 02:14
Publish the Manuscript Online	2024-03-15 09:49

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Observational Study
Article Title	Comparative efficacy of sodium glucose cotransporter-2 inhibitors in the management of type 2 diabetes mellitus: A real-world experience
Manuscript Source	Invited Manuscript
All Author List	Lubna Islam, Dhanya Jose, Mohammed Alkhalifah, Dania Blaibel, Vishnu Chandrabalan and Joseph M Pappachan
Funding Agency and Grant Number
Corresponding Author	Joseph M Pappachan, FRCP, MD, Academic Editor, Consultant Physician-Scientist, Professor, Senior Researcher, Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Sharoe Green Lane, Preston PR2 9HT, United Kingdom. drpappachan@yahoo.co.in
Key Words	Sodium glucose cotransporter-2 inhibitors; Empagliflozin; Canagliflozin; Dapagliflozin; Type 2 diabetes mellitus; Cardiovascular disease; Albumin creatinine ratio; Diabesity
Core Tip	Treatment of type 2 diabetes mellitus with sodium glucose cotransporter-2 inhibitors (SGLT-2i) is associated with significant glycated hemoglobin (HbA1c) reduction, body weight loss, and cardiovascular benefits as proven by multiple randomised controlled trials (RCTs). Our real-world data analysis of the efficacy and safety of individual SGLT-2i revealed better reduction of HbA1c with dapagliflozin, canagliflozin, and empagliflozin, while better body weight reduction was seen only with dapagliflozin and canagliflozin when compared to RCTs. Blood pressure reduction, and side effect profiles were comparable to previous studies. A significant improvement of albuminuria was obvious only with canagliflozin, presumably because of the low number of participants in this study. Analyses of various large-scale real-world data are expected to inform better clinical decision making in future.
Publish Date	2024-03-15 09:49
Citation	Islam L, Jose D, Alkhalifah M, Blaibel D, Chandrabalan V, Pappachan JM. Comparative efficacy of sodium glucose cotransporter-2 inhibitors in the management of type 2 diabetes mellitus: A real-world experience. World J Diabetes 2024; 15(3): 463-474
URL	https://www.wjgnet.com/1948-9358/full/v15/i3/463.htm
DOI	https://dx.doi.org/10.4239/wjd.v15.i3.463

Full Article (PDF)	WJD-15-463-with-cover.pdf
Full Article (Word)	WJD-15-463.docx
STROBE Statement	89337-STROBE statement.pdf
Manuscript File	89337_Auto_Edited-YJP.docx
Answering Reviewers	89337-Answering reviewers.pdf
Audio Core Tip	89337-Audio core tip.m4a
Biostatistics Review Certificate	89337-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	89337-Conflict-of-interest statement.pdf
Copyright License Agreement	89337-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s)	89337-Informed consent statement.pdf
Institutional Review Board Approval Form or Document	89337-Institutional review board statement.pdf
Peer-review Report	89337-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	89337-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	89337-Bing-Wang JJ-2.png
Scientific Editor Work List	89337-Scientific editor work list.pdf